Please login to the form below

Not currently logged in
Email:
Password:

Celltrion

This page shows the latest Celltrion news and features for those working in and with pharma, biotech and healthcare.

Celltrion launches phase 3 trial of COVID-19 mAb

Celltrion launches phase 3 trial of COVID-19 mAb

In September, Celltrion also announced interim results from a phase 1 clinical trial of CT-P59, which showed a promising safety, tolerability and pharmacokinetics profile for the drug. ... If all goes to plan, Celltrion anticipates the development of

Latest news

More from news
Approximately 14 fully matching, plus 39 partially matching documents found.

Latest Intelligence

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    This has provided an opportunity for companies specialising in development of biosimilars to win deals from big companies, such as the $160m agreement between Teva and Celltrion in the US and

  • Deal Watch October 2016 Deal Watch October 2016

    For example in Europe both Pfizer (Hospira) in 2009 and Mundipharma in 2014 have rights to Celltrion's infliximab. ... 175. Celltrion (SK). Teva (IS). Co-commercialisation. Biosimilar rituximab and trastuzumab in phase III in North America.

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    This first infliximab biosimilar was developed and manufactured by Celltrion and is marketed by various partners, notably Hospira under the brand name Inflectra and Mundipharma as Remsima.

  • Pharma deals in February 2015 Pharma deals in February 2015

    Assets that Hospira acquired with Celltrion are essentially replicas of existing Pfizer programmes eg Herceptin and Rituxan and these will probably be divested.

  • Current development and marketing of biosimilar monoclonal antibodies in Latin America Current development and marketing of biosimilar monoclonal antibodies in Latin America

    Celltrion. South Korea. CT-P10. Clinical. FL: Phase III started in Dec 2011. ... 7). OliMed. Trastuzumab. Celltrion. South Korea. CT-P06. Clinical. BC: Ph III completed in Dec 2011.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

COVID-19 vaccine
How will COVID-19 affect uptake of vaccinations against other diseases?
Will COVID-19 help or hinder the quest to increase uptake of other vaccinations?...
How community outreach can help improve diversity in clinical research
To execute a considered community engagement strategy, an involved and collaborative process is needed....
OPEN Health delivers over 250 virtual activities during COVID-19 – A clear path forward
...

Infographics